Bellerophon's board ap­proves liq­ui­da­tion plan, leaves Nas­daq af­ter lay­offs and tri­al fail­ures

Bellerophon Ther­a­peu­tics’ board of di­rec­tors has ap­proved a plan to liq­ui­date the com­pa­ny and now just needs share­hold­er ap­proval to dis­solve af­ter it let go …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER